Bone health in advanced prostate cancer: pathophysiology and management strategies
Abstract
Bone loss and bone metastases can increase morbidity and impair quality of life for patients with prostate cancer. Use of hormonal agents can compromise bone integrity from treatment initiation, and the emergence of bone metastases further increases the risk of symptomatic skeletal-related events. Management of bone health should therefore be pivotal across the prostate cancer continuum. Current guidelines recommend that all men starting or receiving androgen-deprivation therapy for prostate cancer be assessed regularly for bone loss using predictive tools such as dual-energy X-ray absorptiometry and Trabecular Bone Score. Bone health agents (BHAs) are recommended for all men with castration-resistant prostate cancer with skeletal metastases to prevent symptomatic skeletal-related events and for high-risk men receiving androgen-deprivation therapy to prevent treatment-related bone loss. Options include bisphosphonates such as zoledronic acid and alendronate and the receptor activator of nuclear factor kappa-B ligand inhibitor denosumab. Patients should be monitored for adverse effects of BHAs, such as osteonecrosis of the jaw and hypocalcemia. Alongside BHAs, there are treatment options for metastatic castration-resistant prostate cancer associated with beneficial bone-related effects, notably abiraterone acetate, enzalutamide, and radium-223. In this narrative review, we focus on how bone health management can be integrated into standard clinical practice in men with…
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.